Sekundarpravention nach ischamischem zerebralem insult: Die ESPRIT- studie: Niedrig dosierte antikoagulation, kombinationstherapie reit acetylsalicylsaure/dipyridamol oder monotherapie reit acetylsalicylsaure?

J. W. Gorter; Els De Schryver; A. Algra

doi:10.1007/s001150050451

Sekundarpravention nach ischamischem zerebralem insult: Die ESPRIT- studie: Niedrig dosierte antikoagulation, kombinationstherapie reit acetylsalicylsaure/dipyridamol oder monotherapie reit acetylsalicylsaure?

Translated title of the contribution: Prevention of vascular complications after cerebral ischaemia of arterial orgin; the ESPRIT study: Mild anticoagulant therapy, combination treatment with acetylsalicylic acid and dipyridamole, or treatment with acetylsalicylic acid alone?

J. W. Gorter, Els De Schryver, A. Algra

Research output: Contribution to journal › Article › Academic › peer-review

4 Citations (Scopus)

Abstract

The European and Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) is a randomised clinical trial in which patients with cerebral ischaemia of arterial origin will be randomised between oral anticoagulation (international normalized ratio (INR): 2.0-3.0), the combination of acetylsalicylic acid (in any dose between 30 and 325 mg per day) plus dipyridamole (400 mg daily) and acetylsalicylic acid only (in any dose between 30 and 325 mg per day). It is planned to enroll 4500 patients with a mean followup of three years. Primary outcome is the composite event of vascular death, stroke, myocardial infarction, or major bleeding complication; outcome assessment will be blinded. ESPRIT is an international, multicentre study in which 60-80 hospitals in the Netherlands and other countries in Europe and Australia will participate.

Translated title of the contribution	Prevention of vascular complications after cerebral ischaemia of arterial orgin; the ESPRIT study: Mild anticoagulant therapy, combination treatment with acetylsalicylic acid and dipyridamole, or treatment with acetylsalicylic acid alone?
Original language	German
Pages (from-to)	368-370
Number of pages	3
Journal	Nervenarzt
Volume	70
Issue number	4
DOIs	https://doi.org/10.1007/s001150050451
Publication status	Published - Apr 1999
Externally published	Yes

Keywords

Anticoagulant
Dipyridamole
ESPRIT
Prevention
Stroke

Access to Document

10.1007/s001150050451

Fingerprint

Dive into the research topics of 'Prevention of vascular complications after cerebral ischaemia of arterial orgin; the ESPRIT study: Mild anticoagulant therapy, combination treatment with acetylsalicylic acid and dipyridamole, or treatment with acetylsalicylic acid alone?'. Together they form a unique fingerprint.

Cite this

@article{f9b1be284f6340a98fe4140c694f6169,

title = "Sekundarpravention nach ischamischem zerebralem insult: Die ESPRIT- studie: Niedrig dosierte antikoagulation, kombinationstherapie reit acetylsalicylsaure/dipyridamol oder monotherapie reit acetylsalicylsaure?",

abstract = "The European and Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) is a randomised clinical trial in which patients with cerebral ischaemia of arterial origin will be randomised between oral anticoagulation (international normalized ratio (INR): 2.0-3.0), the combination of acetylsalicylic acid (in any dose between 30 and 325 mg per day) plus dipyridamole (400 mg daily) and acetylsalicylic acid only (in any dose between 30 and 325 mg per day). It is planned to enroll 4500 patients with a mean followup of three years. Primary outcome is the composite event of vascular death, stroke, myocardial infarction, or major bleeding complication; outcome assessment will be blinded. ESPRIT is an international, multicentre study in which 60-80 hospitals in the Netherlands and other countries in Europe and Australia will participate.",

keywords = "Anticoagulant, Dipyridamole, ESPRIT, Prevention, Stroke",

author = "Gorter, {J. W.} and {De Schryver}, Els and A. Algra",

year = "1999",

month = apr,

doi = "10.1007/s001150050451",

language = "German",

volume = "70",

pages = "368--370",

journal = "Nervenarzt",

issn = "0028-2804",

publisher = "Springer-Verlag",

number = "4",

}

Sekundarpravention nach ischamischem zerebralem insult: Die ESPRIT- studie: Niedrig dosierte antikoagulation, kombinationstherapie reit acetylsalicylsaure/dipyridamol oder monotherapie reit acetylsalicylsaure? / Gorter, J. W.; De Schryver, Els; Algra, A.
In: Nervenarzt, Vol. 70, No. 4, 04.1999, p. 368-370.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Sekundarpravention nach ischamischem zerebralem insult

T2 - Die ESPRIT- studie: Niedrig dosierte antikoagulation, kombinationstherapie reit acetylsalicylsaure/dipyridamol oder monotherapie reit acetylsalicylsaure?

AU - Gorter, J. W.

AU - De Schryver, Els

AU - Algra, A.

PY - 1999/4

Y1 - 1999/4

N2 - The European and Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) is a randomised clinical trial in which patients with cerebral ischaemia of arterial origin will be randomised between oral anticoagulation (international normalized ratio (INR): 2.0-3.0), the combination of acetylsalicylic acid (in any dose between 30 and 325 mg per day) plus dipyridamole (400 mg daily) and acetylsalicylic acid only (in any dose between 30 and 325 mg per day). It is planned to enroll 4500 patients with a mean followup of three years. Primary outcome is the composite event of vascular death, stroke, myocardial infarction, or major bleeding complication; outcome assessment will be blinded. ESPRIT is an international, multicentre study in which 60-80 hospitals in the Netherlands and other countries in Europe and Australia will participate.

AB - The European and Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) is a randomised clinical trial in which patients with cerebral ischaemia of arterial origin will be randomised between oral anticoagulation (international normalized ratio (INR): 2.0-3.0), the combination of acetylsalicylic acid (in any dose between 30 and 325 mg per day) plus dipyridamole (400 mg daily) and acetylsalicylic acid only (in any dose between 30 and 325 mg per day). It is planned to enroll 4500 patients with a mean followup of three years. Primary outcome is the composite event of vascular death, stroke, myocardial infarction, or major bleeding complication; outcome assessment will be blinded. ESPRIT is an international, multicentre study in which 60-80 hospitals in the Netherlands and other countries in Europe and Australia will participate.

KW - Anticoagulant

KW - Dipyridamole

KW - ESPRIT

KW - Prevention

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=0032909054&partnerID=8YFLogxK

U2 - 10.1007/s001150050451

DO - 10.1007/s001150050451

M3 - Article

C2 - 10355002

AN - SCOPUS:0032909054

SN - 0028-2804

VL - 70

SP - 368

EP - 370

JO - Nervenarzt

JF - Nervenarzt

IS - 4

ER -

Sekundarpravention nach ischamischem zerebralem insult: Die ESPRIT- studie: Niedrig dosierte antikoagulation, kombinationstherapie reit acetylsalicylsaure/dipyridamol oder monotherapie reit acetylsalicylsaure?

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this